Skip to main content
TipRanks
Go Ultimate75% OFF

British American Tobacco (BMTA) Q2 2026 Earnings Report

3 Followers

DE:BMTA Q2 2026 EPS Results

Actual EPS
EUR 2.04
Consensus EPS
EUR 1.94
Beat/Miss
Beat by +EUR 0.10
One Year Ago EPS
EUR 1.95

DE:BMTA Q2 2026 Revenue Results

Actual Revenue
EUR 14.93B
Expected Revenue
EUR 14.90B
Beat/Miss
Beat by +EUR 32.22M
YoY Revenue Growth
+5.16%

Earnings Announcement Details

Quarter
Q2 2026
Date
07/30/2026
Time
Before Open
Conference Call
Thursday, July 30, 2026
DE:BMTA Upcoming Earnings

British American Tobacco's next earnings date is estimated for February 11, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

DE:BMTA Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Jul 30, 2026|% Change Since:0.63%|
Earnings Call Sentiment|Positive

The call presented multiple clear progress points: strong New Category growth (notably Modern Oral), solid US multi-category performance, margin expansion, improved cash generation, and a defined Fit2Win savings trajectory. These positives are balanced by material near-term challenges: declines in Heated Products and Vapour revenues in some regions, APMEA profit pressure, combustible volume declines and market-specific shocks (e.g., Brazil excise), ongoing regulatory and illicit market issues, and sizable one-off/non-cash charges. Management reiterated confidence in recovery and a pathway to return to the midterm algorithm while emphasizing targeted investments for sustainable growth.

Company Guidance

Guidance: management expects a H2‑weighted recovery with adjusted profit from operations accelerating in H2 and full‑year adjusted EPS now expected toward the middle of the 5–8% range, while revenue and operating profit are expected at the lower end of the algorithm after absorbing c.1% transactional FX headwind; key H2 drivers are mid‑teens New Category revenue growth (after H1 New Categories +18% and Modern Oral +66%), an AME acceleration and APMEA sequential recovery, plus positive phasing of Fit2Win benefits. Financial targets include net finance cost of c.£1.65bn, an underlying tax rate of 24–25%, reaching target leverage of 2.0–2.5x by year‑end, a £1.3bn 2026 share buyback alongside the progressive dividend, and a commitment to deliver >£50bn free cash flow by 2030; Fit2Win is now expected to deliver £700m annualized savings by 2028 (£500m by 2027) with total one‑off costs ~£950m (£840m adjusting).

  • Smokeless Revenue Progress and Consumer AddsSmokeless now represents 19.8% of group revenue (up 160 basis points year-on-year). The business added 4.1 million smokeless consumers over the last 12 months, taking the total to 35 million, driven mainly by Modern Oral and the Velo brand.
  • New Categories: Strong Growth and ProfitabilityNew categories revenue accelerated to +18% (Modern Oral +66%; Vapour +5.3%). New category contribution increased 55% to GBP 269 million and gross profit in the category rose by over GBP 120 million, reflecting improved scale and targeted investment.
  • Solid Group Financial Performance (Adjusted)Group constant-currency results: revenue +2.9%, adjusted gross profit +3.8%, adjusted profit from operations +3.5%, and adjusted diluted EPS +7.9%. Full-year EPS guidance upgraded to the middle of the 5%–8% range.
  • US Multi-Category StrengthUS total revenue +8.5% and adjusted operating profit +10.1%. US New Category revenue nearly +60% (Velo Plus +200%; Vuse returned to double-digit volume and revenue growth). Vuse extended Vapour value share to a record 55.9%.
  • Combustibles Price/Mix and Revenue ResilienceCombustible revenue grew 2.1% despite combustibles volume decline of 4.7%; price/mix contributed +6.8%. Strong price/mix and cost optimization supported adjusted gross profit growth ahead of revenue.
  • Margin Progress and Fit2Win TransformationGroup operating margin expanded 30 basis points to 43.7% (10 bps expansion at current rates). Fit2Win savings now expected GBP 700 million annualized by 2028 (GBP 500 million by 2027); identified a further GBP 100 million of optimization savings.
  • Cash Generation, Leverage and Shareholder ReturnsStrong cash conversion (>95% target), on track to be within 2.0–2.5x leverage corridor by year-end. Committed GBP 1.3 billion share buyback in 2026, progressive dividend maintained, and ambition to deliver >GBP 50 billion free cash flow by 2030.
  • Modern Oral Global Leadership and ScaleBAT shipped 7.9 billion Modern Oral pouches in H1. Modern Oral top-market volume share increased by over 8 percentage points to 39%; in AME BAT holds 62% volume share across top markets and 68.5% value share. Velo captures ~90% of Modern Oral value growth in the US.

DE:BMTA Earnings History

DE:BMTA earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 11, 20272026 (Q4)2.35-2.31――
Jul 30, 20262026 (Q2)1.942.041.954.60% (+0.09)
Feb 12, 20262025 (Q4)2.282.31-0.77401.18% (+3.08)
Jul 31, 20252025 (Q2)2.011.951.98-1.24% (-0.02)
Feb 13, 20252024 (Q4)2.21-0.77-9.3591.78% (+8.58)
Jul 25, 20242024 (Q2)1.981.982.13-7.12% (-0.15)
Feb 08, 20242023 (Q4)2.26-9.351.16-905.47% (-10.51)
Jul 26, 20232023 (Q2)2.032.131.8316.53% (+0.30)
Feb 09, 20232022 (Q4)2.231.162.15-45.99% (-0.99)
Jul 27, 20222022 (Q2)1.851.831.94-5.84% (-0.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed